Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 273.13% from the company's current price. HC Wainwright also issued estimates for Pyxis Oncology's Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.42) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at $0.33 EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.28) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at $0.20 EPS.
Pyxis Oncology Stock Up 1.5%
Pyxis Oncology stock traded up $0.02 during mid-day trading on Tuesday, hitting $1.34. 1,333,169 shares of the stock were exchanged, compared to its average volume of 406,891. Pyxis Oncology has a 12 month low of $0.8332 and a 12 month high of $5.3899. The firm's fifty day simple moving average is $1.16 and its two-hundred day simple moving average is $1.15. The stock has a market capitalization of $83.11 million, a price-to-earnings ratio of -0.84 and a beta of 1.13.
Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $2.82 million for the quarter. As a group, analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.
Institutional Trading of Pyxis Oncology
Several hedge funds have recently modified their holdings of PYXS. ProShare Advisors LLC bought a new stake in shares of Pyxis Oncology in the 4th quarter valued at $26,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Pyxis Oncology in the 2nd quarter valued at $26,000. Ameriprise Financial Inc. bought a new stake in shares of Pyxis Oncology in the 4th quarter valued at $35,000. Caption Management LLC bought a new stake in shares of Pyxis Oncology in the 4th quarter valued at $35,000. Finally, Kingstone Capital Partners Texas LLC bought a new stake in shares of Pyxis Oncology in the 2nd quarter valued at $37,000. Institutional investors own 39.09% of the company's stock.
Pyxis Oncology Company Profile
(
Get Free Report)
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Read More
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
